Mosaic Turner syndrome with improved Chiari type 1 malformation after growth          hormone therapy: A case report

Mori, Toshihiko; Shimomura, Ryotaro; Iwasa, Mami; Ito, Takuro; Iizuka, Hyronori; Hoshino, Emiko; Hirakawa, Satoshi; Sakurai, Natsuki; Fuse, Shigeto

doi:10.1297/cpe.30.49

Cited by 2 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2008, Gupta et al [18] reported a case of resolution of CM-1 and related syringomyelia in a 9-year-old boy with GHD after GH therapy. Recently in another patient with GHD and mosaic Turn-er syndrome, GH therapy led to the resolution of CM-1 [19].…”

Section: Discussionmentioning

confidence: 99%

Can GH Therapy Worsen a Clinically Silent Chiari Malformation? A Case Report and Systematic Literature Review

et al. 2022

View full text Add to dashboard Cite

Background: The link between the effects of recombinant human growth hormone (rhGH) therapy in patient with growth hormone deficiency (GHD) and Chiari malformation type I (CM-1) is controversial. Summary: We report the case of a patient with an unusual association of growth hormone deficiency (GHD) due to ectopic posterior pituitary and Chiari malformation type I (CM-1). Our patient developed headache and worsening of CM-1 after initiation of rhGH therapy. Following an atlo-occipital decompression surgery, the patient was able to resume therapy with a marked growth improvement. Based on this observation, we provide a systematic review of the current literature about these two pathologies. Key Messages: A careful follow-up of all patients with CM-1 treated with GH is mandatory, paying particular attention to the appearance of any neurological signs and symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%